Wang, Foster City
Cheng-I Wang, Foster City, CA US
Patent application number | Description | Published |
---|---|---|
20090052029 | FUNCTIONAL FILMS FORMED BY HIGHLY ORIENTED DEPOSITION OF NANOWIRES - Optical films formed by deposition of highly oriented nanowires and methods of aligning suspended nanowires in a desired direction by flow-induced shear force are described. | 02-26-2009 |
20090305437 | FABRICATION OF INORGANIC MATERIALS USING TEMPLATES WITH LABILE LINKAGE - A method of forming an integrated circuit layer material is described, comprising depositing a layer of templates on a substrate, said template including a first binding site having an affinity for the substrate, a second binding site having an affinity for a target integrated circuit material and a protecting material coupled to the second binding site via a labile linkage to prevent the binding site from binding to the target integrated circuit material; exposing the template to an external stimulus to degrade the labile linkage; removing the protecting material; and binding the integrated circuit material to the second binding site. | 12-10-2009 |
Gonghou Wang, Foster City, CA US
Patent application number | Description | Published |
---|---|---|
20090136821 | Electrolyte supported cell designed for longer life and higher power - A solid oxide fuel cell (SOFC) includes a cathode electrode, an anode electrode, and a solid oxide electrolyte located between the anode electrode and the cathode electrode. The cathode electrode is a porous ceramic layer infiltrated with a cathode catalyst material, and the anode electrode is a porous ceramic layer infiltrated with an anode catalyst material, and the electrolyte is a ceramic layer having a lower porosity than the anode and the cathode electrodes. A ceramic reinforcing region may be located adjacent to the riser opening in the electrolyte. | 05-28-2009 |
20120024461 | ELECTROLYTE SUPPORTED CELL DESIGNED FOR LONGER LIFE AND HIGHER POWER - A solid oxide fuel cell (SOFC) includes a cathode electrode, an anode electrode, and a solid oxide electrolyte located between the anode electrode and the cathode electrode. The cathode electrode is a porous ceramic layer infiltrated with a cathode catalyst material, and the anode electrode is a porous ceramic layer infiltrated with an anode catalyst material, and the electrolyte is a ceramic layer having a lower porosity than the anode and the cathode electrodes. A ceramic reinforcing region may be located adjacent to the riser opening in the electrolyte. | 02-02-2012 |
20120028162 | Electrolyte Supported Cell Designed for Longer Life and Higher Power - A solid oxide fuel cell (SOFC) includes a cathode electrode, an anode electrode, and a solid oxide electrolyte located between the anode electrode and the cathode electrode. The cathode electrode is a porous ceramic layer infiltrated with a cathode catalyst material, and the anode electrode is a porous ceramic layer infiltrated with an anode catalyst material, and the electrolyte is a ceramic layer having a lower porosity than the anode and the cathode electrodes. A ceramic reinforcing region may be located adjacent to the riser opening in the electrolyte. | 02-02-2012 |
20120280183 | CERAMIC BORON-CONTAINING DOPING PASTE AND METHODS THEREFOR - A ceramic boron-containing dopant paste is disclosed. The ceramic boron-containing dopant paste further comprising a set of solvents, a set of ceramic particles dispersed in the set of solvents, a set of boron compound particles dispersed in the set of solvents, a set of binder molecules dissolved in the set of solvents. Wherein, the ceramic boron-containing dopant paste has a shear thinning power law index n between about 0.01 and about 1. | 11-08-2012 |
20130119319 | CERAMIC BORON-CONTAINING DOPING PASTE AND METHODS THEREOF - A ceramic boron-containing dopant paste is disclosed. The ceramic boron-containing dopant paste further comprising a set of solvents, a set of ceramic particles dispersed in the set of solvents, a set of boron compound particles dispersed in the set of solvents, a set of binder molecules dissolved in the set of solvents. Wherein, the ceramic boron-containing dopant paste has a shear thinning power law index n between about 0.01 and about 1. | 05-16-2013 |
20140065764 | METHOD FOR MANUFACTURING A PHOTOVOLTAIC CELL WITH A LOCALLY DIFFUSED REAR SIDE - A method for manufacturing a photovoltaic cell with a locally diffused rear side, comprising steps of: (a) providing a doped silicon substrate, the substrate comprising a front, sunward facing, surface and a rear surface; (b) forming a silicon dioxide layer on the front surface and the rear surface; (c) depositing a boron-containing doping paste on the rear surface in a pattern, the boron-containing paste comprising a boron compound and a solvent; (d) depositing a phosphorus-containing doping paste on the rear surface in a pattern, the phosphorus-containing doping paste comprising a phosphorus compound and a solvent; (e) heating the silicon substrate in an ambient to a first temperature and for a first time period in order to locally diffuse boron and phosphorus into the rear surface of the silicon substrate. | 03-06-2014 |
20150364615 | ALUMINUM-TIN PASTE AND ITS USE IN MANUFACTURING SOLDERABLE ELECTRICAL CONDUCTORS - The present invention is directed to a paste composition comprising Al and Sn dispersed in an organic medium and to paste compositions that provide a solderable electrode. The present invention is further directed to an electrode formed from the paste composition and a semiconductor device and, in particular, a solar cell comprising such an electrode. The paste compositions that provide a solderable electrode are particularly useful for forming a solar cell back side solderable electrode. | 12-17-2015 |
Guohui Wang, Foster City, CA US
Patent application number | Description | Published |
---|---|---|
20150081908 | COMPUTER-BASED, BALANCED PROVISIONING AND OPTIMIZATION OF DATA TRANSFER RESOURCES FOR PRODUCTS AND SERVICES - A computer program product for provisioning resources in a balanced data transfer pipeline may associate a first requested task with a first category, allocate a first resource of a data path to the first requested task based on the first resource corresponding to the first category; and allocate a second resource as part of the data path to the first requested task based on the second resource corresponding to the first category, wherein the first resource corresponds to a first segment of the data path and the second resource corresponds to a second segment of the data path. | 03-19-2015 |
20150081912 | COMPUTER-BASED, BALANCED PROVISIONING AND OPTIMIZATION OF DATA TRANSFER RESOURCES FOR PRODUCTS AND SERVICES - A computer program product for provisioning resources in a balanced data transfer pipeline may associate a first requested task with a first category, allocate a first resource of a data path to the first requested task based on the first resource corresponding to the first category; and allocate a second resource as part of the data path to the first requested task based on the second resource corresponding to the first category, wherein the first resource corresponds to a first segment of the data path and the second resource corresponds to a second segment of the data path. | 03-19-2015 |
Haixun Wang, Foster City, CA US
Patent application number | Description | Published |
---|---|---|
20150120775 | ANSWERING RELATIONAL DATABASE QUERIES USING GRAPH EXPLORATION - Embodiments are directed to processing queries using schema graph traversal and to establishing a schema graph that allows queries to be answered by traversing graph nodes. In one scenario, a computer system receives a query which specifies relational tables and corresponding relationships that are to be retrieved from a relational database. The computer system accesses a schema graph that includes graph nodes representing relational tables, as well as edges that identify relationships between the relational tables. The graph nodes include relational data that was loaded from one storage area (e.g. a non-volatile storage area), and the schema graph is stored in a second storage area (e.g. a volatile storage area). The computer system then traverses the schema graph, beginning at a set of graph nodes and continuing along the edges to other graph nodes until the query has been satisfied, and then reports the results of the graph traversal. | 04-30-2015 |
Hongbing Wang, Foster City, CA US
Patent application number | Description | Published |
---|---|---|
20120179743 | TECHNIQUES FOR DETECTING NEW BROWSER WINDOWS - Embodiments of the present invention provide techniques for tracking the lifecycles of client-side browser windows in the context of a web application. In one set of embodiments, a server component of a web application can receive a request originating from a client-side browser window, where the request includes a resource locator (e.g., a URL) and a window identifier. In response, the server component can send a script to the window for retrieving the window's actual identifier/name. Based on the actual identifier returned by the script and the window identifier included in the initial request, the server component can determine whether the window is a new window or an existing window and can process the request as appropriate. | 07-12-2012 |
20120179744 | TECHNIQUES FOR DETECTING INACTIVE BROWSER WINDOWS - Embodiments of the present invention provide techniques for tracking the lifecycles of client-side browser windows in the context of a web application. In one set of embodiments, a server component of a web application can receive a notification that an application page in a first window has been unloaded/destroyed. In response, the server component can associate the first window with an expiration time and add the first window to an “expiration” list of windows that are potentially inactive. If a request is received by the server component from the first window while the first window is in the expiration list, the server component can identify the first window as active and remove it from the list. If a request is received by the server component from a second window after the expiration time associated with the first window, the server component can identify the first window as inactive and free all resources for the first window. | 07-12-2012 |
20140181703 | DYNAMICALLY GENERATED USER INTERFACE - A system and method for facilitating automatically adjusting a user interface display screen or portion thereof. An example method includes determining context information associated with data, wherein the data is maintained in accordance with a data model; generating a signal when the context information changes; and employing the signal to automatically configure one or more characteristics of a user interface architecture, resulting in an adjusted user interface architecture. The context information may include information specifying one or more attributes relating to the data model. Generating may further include analyzing the one or more attributes to determine a modification to be made to the user interface architecture and then rendering a user interface display screen based on a modified user interface architecture. | 06-26-2014 |
20140181784 | DYNAMIC USER INTERFACE TAG FORMAT - A system and method for facilitating characterizing data to enable dynamic generation of a user interface feature based on the data. An example method includes maintaining data in accordance with a data model accessible to webpage computer code, wherein the data model is adapted to be populated with data associated with one or more data attributes in the data model; and providing a signal, identifying a data attribute, from the data model to webpage computer code to facilitate dynamic construction of one or more user interface features characterizing a rendering of a webpage. Data in the data model is characterized by one or more data attributes, each of which is associated with an attribute definition. The example method may further include organizing one or more attribute definitions in the data model as computing objects containing characterizations of the one or more data attributes. | 06-26-2014 |
20140181788 | DYNAMIC USER INTERFACE AUTHORING - A system and method for facilitating authoring computer code to facilitate rendering a display of data via a user interface display screen. An example method includes accepting a signal from a user input device to specify an attribute in accordance with a definition of a class of attributes in a data model; providing the specification of the attribute to a software component characterizing a webpage, wherein the software component includes an indicator for dynamic rendering of at least a portion of data included in the data model and associated with the attribute; and storing the definition of the class of attributes and data associated with the attribute, for retrieval and rendering of the data on a target device. The example method may include providing a mechanism for modifying attributes of the data model and propagating data model changes to webpage computer code. | 06-26-2014 |
20150067547 | TECHNIQUES FOR DETECTING INACTIVE BROWSER WINDOWS - Embodiments provide techniques for tracking the lifecycles of client-side browser windows in the context of a web application. In an embodiment, a server component of a web application can receive a notification that an application page in a first window has been unloaded. In response, the server component can associate the first window with an expiration time and add the first window to an expiration list of windows that are potentially inactive. If a request is received by the server component from the first window while the first window is in the expiration list, the server component can identify the first window as active and remove it from the list. If a request is received by the server component from a second window after the expiration time associated with the first window, the server component can identify the first window as inactive and free all resources for the first window. | 03-05-2015 |
20150188781 | TECHNIQUES FOR DETECTING NEW BROWSER WINDOWS - Embodiments of the present invention provide techniques for tracking the lifecycles of client-side browser windows in the context of a web application. In one set of embodiments, a server component of a web application can receive a request originating from a client-side browser window, where the request includes a resource locator (e.g., a URL) and a window identifier. In response, the server component can send a script to the window for retrieving the window's actual identifier/name. Based on the actual identifier returned by the script and the window identifier included in the initial request, the server component can determine whether the window is a new window or an existing window and can process the request as appropriate. | 07-02-2015 |
Jianchao Wang, Foster City, CA US
Patent application number | Description | Published |
---|---|---|
20090253737 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS - Provided are certain chemical entities, and methods of use to modulate skeletal myosin, skeletal actin, skeletal tropomyosin, skeletal troponin C, skeletal troponin I, skeletal troponin T, and skeletal muscle, including fragments and isoforms thereof, as well as the skeletal sarcomere, and methods of use in the treatment of neuromuscular disorders, conditions having muscle wasting, claudication, frailty, metabolic syndrome, muscle atrophy associated with disuse, and muscle fatigue, and other indications. | 10-08-2009 |
20100069453 | Certain Chemical Entities, Compositions, and Methods - Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed. | 03-18-2010 |
20110312975 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS - Provided are certain chemical entities, and methods of use to modulate skeletal myosin, skeletal actin, skeletal tropomyosin, skeletal troponin C, skeletal troponin I, skeletal troponin T, and skeletal muscle, including fragments and isoforms thereof, as well as the skeletal sarcomere, and methods of use in the treatment of neuromuscular disorders, conditions having muscle wasting, claudication, frailty, metabolic syndrome, muscle atrophy associated with disuse, and muscle fatigue, and other indications. | 12-22-2011 |
Jianhong Wang, Foster City, CA US
Patent application number | Description | Published |
---|---|---|
20160067255 | METHODS OF TREATING OR PREVENTING HIV IN PATIENTS USING A COMBINATION OF TENOFOVIR ALAFENAMIDE AND DOLUTEGRAVIR - The disclosure describes methods for treating or preventing HIV in a patient using a combination of tenofovir alafenamide and dolutegravir, and to compositions containing such compounds. | 03-10-2016 |
Jianying Wang, Foster City, CA US
Patent application number | Description | Published |
---|---|---|
20090149400 | ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF - Compounds and compositions of Formula I are described, useful as anti-proliferative agents, and in particular anti-HPV, | 06-11-2009 |
John Wang, Foster City, CA US
Patent application number | Description | Published |
---|---|---|
20140249999 | Multiple Merchant Payment Processor Platform Apparatuses, Methods and Systems - The MULTIPLE MERCHANT PAYMENT PROCESSOR PLATFORM APPARATUSES, METHODS AND SYSTEMS (“MID-PLATFORM”) enable merchants to customize the way payments made to them are processed. For example, a computer-implemented MID-Platform receives a payment request associated with a site (e.g., a website) and identifies a site profile associated with the site. The site profile is associated with one or more account processors and one or more transaction preference rules for selecting one of the account processors. The MID-Platform processes information associated with the payment request according to one or more transaction preference rules to select one of the account processors. Then, the MID-Platform sends a payment processing request to the selected account processor. | 09-04-2014 |
Juan Wang, Foster City, CA US
Patent application number | Description | Published |
---|---|---|
20090042916 | [4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENY- L]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS AND METHODS RELATED THERETO - The present invention provides novel sulfonylurea salts of a salt of formula (I) | 02-12-2009 |
20090156620 | [4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENY- L]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS AND METHODS RELATED THERETO - The present invention provides novel sulfonylurea salts of a salt of formula (I) | 06-18-2009 |
20100151019 | SOLID COMPOSITION FOR CONTROLLED RELEASE OF IONIZABLE ACTIVE AGENTS WITH POOR AQUEOUS SOLUBILITY AT LOW pH AND METHODS OF USE THEREOF - A novel solid composition and methods for making and using the solid composition are provided. The solid composition comprises: (a) at least one active agent with a solubility of less than about 0.3 mg/ml in an aqueous solution with a pH of at most about 6.8 at a temperature of about 37° C.; and (b) a hydrophilic polymer matrix composition comprising: i) a hydrophilic polymer selected from the group consisting of METHOCEL™, POLYOX™ WSR 1105 and combinations thereof; and optionally ii) a hydrophobic polymer selected from the group consisting of Ethocel 20 premium; and (c) an alkalizer selected from the group consisting of calcium carbonate, magnesium oxide heavy and sodium bicarbonate; wherein the composition provides at least about 70% release of the active between about 7 to about 12 hours following oral administration. | 06-17-2010 |
20110160250 | CRYSTALLINE FORMS OF A FACTOR XA INHIBITOR - The present invention provides crystalline forms of a mesylate salt of the compound 5-chloro-N-((1-(4-(2-oxopyridin-1(2H)-yl)phenyl)-1H-imidazol-4-yl)methyl)thiophene-2-carboxamide and pharmaceutical compositions and methods thereof. | 06-30-2011 |
20120129876 | [4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENY- L]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS AND METHODS RELATED THERETO - The present invention provides novel sulfonylurea salts of a salt of formula (I) | 05-24-2012 |
20130131089 | DOSAGE FORMS OF ELINOGREL AND METHODS OF INJECTABLE ADMINISTRATION THEREOF - The present invention is concerned with a liquid delivery form of Elinogrel for the treatment of thrombosis which is notable for its improved dosage properties and stability. The dosage form is a liquid or a lyophilized form which is reconstituted for an injectable formulation comprising: a) at least about 3 mg/ml or up to about 15 mg/ml Elinogrel or a pharmaceutically acceptable salt thereof (post reconstitution or in liquid form), and b) at least one pharmaceutically acceptable excipient. Further aspects of the present invention concern the preparation and use of such a formulation. | 05-23-2013 |
20130165459 | PHARMACEUTICAL COMPOSITION AND DOSAGE FORMS OF ELINOGREL AND METHODS OF USE THEREOF - The present invention is concerned with a solid delivery form of elinogrel for the treatment of thrombosis which is notable for its multi-pH dissolution, immediate release and improved pharmacokinetic properties and stability in storage. The delivery and dosage form is a solid, oral formulation comprising: a) at least about 15% by weight elinogrel or a pharmaceutically acceptable salt thereof relative to the total weight of the overall pharmaceutical composition, and b) at least one pharmaceutically acceptable carrier. A further aspect of the present invention concerns the preparation and use of such a formulation. | 06-27-2013 |
20130172374 | SOLID COMPOSITION FOR CONTROLLED RELEASE OF IONIZABLE ACTIVE AGENTS WITH POOR AQUEOUS SOLUBILITY AT LOW PH AND METHODS OF USE THEREOF - A novel solid composition and methods for making and using the solid composition are provided. The solid composition comprises: (a) at least one active agent with a solubility of less than about 0.3 mg/ml in an aqueous solution with a pH of at most about 6.8 at a temperature of about 37° C.; and (b) a hydrophilic polymer matrix composition comprising: i) a hydrophilic polymer selected from the group consisting of METHOCEL™, POLYOX™ WSR 1105 and combinations thereof; and optionally ii) a hydrophobic polymer selected from the group consisting of Ethocel 20 premium; and (c) an alkalizer selected from the group consisting of calcium carbonate, magnesium oxide heavy and sodium bicarbonate; wherein the composition provides at least about 70% release of the active between about 7 to about 12 hours following oral administration. | 07-04-2013 |
Liangliang Wang, Foster City, CA US
Patent application number | Description | Published |
---|---|---|
20150134600 | DOCUMENT MANAGEMENT AND COLLABORATION SYSTEM - A method and apparatus for document collaboration and management are disclosed. In the method and apparatus, a document may be incorporated in a document directory maintained by a document collaboration and management service. A portable representation underlay based on the document may be generated using one or more asynchronous workflows and the portable representation underlay may be provided in response to a user request. | 05-14-2015 |
Li-Chong Wang, Foster City, CA US
Patent application number | Description | Published |
---|---|---|
20120100540 | ULTRA SENSITIVE METHOD FOR IN SITU DETECTION OF NUCLEIC ACIDS - Disclosed is a method for in situ detection of one or more target nucleic acids based on a combination of RNAscope® method and a general ISH signal amplification method. This new method produces high signal intensity and while keeps low background noise of signal amplification. The result can be consistently reproduced and the method can be easily adopted for routine clinic diagnostic use. Further, the invention relates to a kit, comprising the components of RNAscope® assay and a general ISH signal amplification assay, for sensitive detection of one or more target nucleic acids. | 04-26-2012 |
20140249040 | ULTRA SENSITIVE METHOD FOR IN SITU DETECTION OF NUCLEIC ACIDS - Disclosed is a method for in situ detection of one or more target nucleic acids based on a combination of RNAscope® method and a general ISH signal amplification method. This new method produces high signal intensity and while keeps low background noise of signal amplification. The result can be consistently reproduced and the method can be easily adopted for routine clinic diagnostic use. Further, the invention relates to a kit, comprising the components of RNAscope® assay and a general ISH signal amplification assay, for sensitive detection of one or more target nucleic acids. | 09-04-2014 |
20150045251 | DUPLEX CHROMOGENIC ASSAY FOR IN SITU DETECTION OF NUCLEIC ACIDS - The disclosure provides methods of detecting two or more target nucleic acids. The methods can include the steps of contacting a sample with two or more label probes having distinct enzyme labels and targeting distinct nucleic acid targets, binding the two or more label probes to the target nucleic acids by hybridization; contacting the sample with a first substrate for the first enzyme of the first label probe; reacting the first substrate with the first enzyme, thereby producing a first detectable signal; contacting the sample with a second substrate for the second enzyme of the second label probe; reacting the second substrate with the second enzyme, thereby producing a second detectable signal; and detecting the first detectable signal and the second detectable signal, thereby detecting the first and second target nucleic acids in the sample. | 02-12-2015 |
Peiyuan Wang, Foster City, CA US
Patent application number | Description | Published |
---|---|---|
20140288020 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS - Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: | 09-25-2014 |
20140315852 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS - Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: | 10-23-2014 |
Rachel Wang, Foster City, CA US
Patent application number | Description | Published |
---|---|---|
20110282833 | PROVIDING ADMINISTRATIVE CAPABILITIES IN A MULTI-TENANT DATABASE ENVIRONMENT - A system and method for providing administrative capabilities in a multi-tenant database system. In one embodiment, a method includes providing a portal for a database system to a user, providing administrative capabilities through the portal, and enabling the user to manage objects in the database system using the administrative capabilities. | 11-17-2011 |
20110282907 | MANAGING ENTITLEMENTS IN A MULTI-TENANT DATABASE ENVIRONMENT - A system and method for managing entitlements in a multi-tenant database system. In one embodiment, a method includes receiving service level definitions for one or more entitlements, and maintaining the one or more entitlements. The method further includes verifying if one or more users are eligible for the one or more entitlements, and enforcing the one or more entitlements based on the service level definitions. | 11-17-2011 |
20130227479 | SYSTEMS AND METHODS FOR DYNAMIC LIST VIEWS AND DETAIL PAGES - Systems and methods are provided for dynamic list views and detail pages. A database system can update a subscribed field in a data record when the field is updated and when a user interface is displaying the field in a list view. The system can provide a notification of an update for a subscribed field in a data record when the field is updated and when a user interface is displaying the field in a list view. The system can update a subscribed field in a data record when the field is updated and when a user interface is displaying the field in a detail page for a list view. The system can provide a notification of an update for a subscribed field in a data record when the field is updated and when a user interface is displaying the field in a detail page for a list view. | 08-29-2013 |
20140201641 | METHODS AND APPARATUS FOR INTERFACING WITH A PHONE SYSTEM IN AN ON-DEMAND SERVICE ENVIRONMENT - Disclosed are systems, apparatus, methods, and computer readable media for interfacing with a phone system in an on-demand service environment. In one embodiment, a client machine is in communication with a data provider and the phone system. The phone system is operated by a phone provider separate from the data provider. A message is received at the client machine from the phone system. The message includes information regarding a phone event in relation to a phone call. The phone event information is provided in a first part of a user interface in a web browser on the client machine. A second part of the user interface is capable of displaying information received at the client machine from the data provider. The first part of the user interface and the second part of the user interface are adapted to communicate with one another. For example, the first part of the user interface is adapted to send a message including the phone event information to the second part of the user interface. | 07-17-2014 |
Shumei Wang, Foster City CA
Patent application number | Description | Published |
---|---|---|
20150105550 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING - The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: | 04-16-2015 |
20150111879 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING - The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: | 04-23-2015 |
Shumei Wang, Foster City, CA US
Patent application number | Description | Published |
---|---|---|
20080269210 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE - Compounds of Formulas Ia-d where X is S or O, mor is a morpholine group, and R | 10-30-2008 |
20090118275 | THIAZOLOPYRIMIDINE P13K INHIBITOR COMPOUNDS AND METHODS OF USE - Compounds of Formulas Ia and Ib, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia and Ib for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. | 05-07-2009 |
20090281089 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING - The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: | 11-12-2009 |
20110092461 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING - The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: | 04-21-2011 |
20110301141 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 INHIBITORS - Compounds of the formula I: | 12-08-2011 |
20120035208 | PYRAZOLOPYRIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE - Compounds of Formula (I), and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer or inflammation mediated by lipid kinases. Methods of using compounds of Formula (I) for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. | 02-09-2012 |
20120094980 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING - The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: | 04-19-2012 |
20130096102 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS - Compounds of the formula I: | 04-18-2013 |
20130157999 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS - Specific Compounds of formula I: | 06-20-2013 |
20150218176 | SERINE/THREONINE KINASE INHIBITORS - Compounds having the formula I wherein R | 08-06-2015 |
Xiang Wang, Foster City, CA US
Patent application number | Description | Published |
---|---|---|
20140094485 | SOLID STATE FORMS OF HIV INHIBITOR - The invention relates to a novel hemi-succinate salt form of (2S)-2-tert-butoxy-2-(4-(2,3-dihydropyrano[4,3,2-de]quinolin-7-yl)-2-methylquinolin-3-yl)acetic acid and a novel crystalline form thereof, methods for the preparation thereof, pharmaceutical compositions thereof and their use in the treatment of Human Immunodeficiency Virus (HIV) infection. | 04-03-2014 |
20140094609 | PROCESS FOR THE PREPARATION OF AN HIV INTEGRASE INHIBITOR - The present invention is directed to an improved process for the preparation of Compounds of Formula (I), which are useful in the treatment of HIV infection. In particular, the present invention is directed to an improved process for the preparation of (2S)-2-tert-butoxy-2-(4-(2,3-dihydropyrano[4,3,2-de]quinolin-7-yl)-2-methylquinolin-3-yl)acetic acid, which is useful in the treatment of HIV infection. | 04-03-2014 |
20150361073 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS - The present disclosure provides processes for the preparation of a compound of formula: | 12-17-2015 |
Xiaohui Wang, Foster City, CA US
Patent application number | Description | Published |
---|---|---|
20130045881 | Probe Based Nucleic Acid Detection - The invention provides a method for detecting a target nucleotide sequence by tagging the nucleotide sequence with a nucleotide tag, providing a probe oligonucleotide with a melting temperature Tm | 02-21-2013 |
20150147755 | PROBE BASED NUCLEIC ACID DETECTION - The invention provides a method for detecting a target nucleotide sequence by tagging the nucleotide sequence with a nucleotide tag, providing a probe oligonucleotide with a melting temperature Tm1, comprising a regulatory sequence and a nucleotide tag recognition sequence; incorporating the probe oligonucleotide into the tagged polynucleotide in a polynucleotide amplification reaction, providing a regulatory oligonucleotide with a melting temperature Tm2, comprising a sequence segment that is at least partially complementary to the regulatory sequence, amplifying the tagged target nucleic acid sequence in a PCR amplification reaction using the probe oligonucleotide as a primer, and detecting the amplification product; wherein Tm1 and Tm2 are higher than the annealing temperature associated with the polynucleotide amplification reaction. | 05-28-2015 |
20150337298 | HAPLOIDOME DETERMINATION BY DIGITIZED TRANSPOSONS - In certain embodiments, the present invention provides a way of “digitally” marking different the alleles of different chromosomes by using a transposase to insert differently barcoded transposons into genomic DNA before further analysis. According to this method, each allele becomes marked with a unique pattern of transposon barcodes. Because each unique pattern of transposon barcodes identifies a particular allele, the method facilitates determinations of ploidy and copy number variation, improves the ability to discriminate among homozygotes, heterozygotes, and patterns arising from sequencing errors, and allows loci separated by uninformative stretches of DNA to be identified as linked loci, thereby facilitating haplotype determinations. Also provided is a novel artificial transposon end that includes a barcode sequence in two or more positions that are not essential for transposition. | 11-26-2015 |
Xiaojing Wang, Foster City, CA US
Patent application number | Description | Published |
---|---|---|
20080214845 | ANTIBACTERIAL 6'-MODIFIED 4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS - The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection. | 09-04-2008 |
20080293649 | ANTIBACTERIAL 4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS HAVING MULTIPLE SUBSTITUENTS - The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection. | 11-27-2008 |
20100004220 | Indenoisoquinolinone Analogs and Methods of Use Thereof - The present invention relates to Indenoisoquinolinone Analogs, compositions comprising an effective amount of an Indenoisoquinolinone Analog and methods for treating or preventing an inflammatory disease, a reperfusion injury, diabetes mellitus, a diabetic complication, reoxygenation injury resulting from organ transplantation, an ischemic condition, a neurodegenerative disease, renal failure, a vascular disease, a cardiovascular disease, cancer, a complication of prematurity, cardiomyopathy, retinopathy, nephropathy, neuropathy, erectile dysfunction or urinary incontinence, comprising administering to a subject in need thereof an effective amount of an Indenoisoquinolinone Analog. | 01-07-2010 |
20100121049 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF - The present invention relates to Indenoisoquinolinone Analogs, compositions comprising an effective amount of an Indenoisoquinolinone Analog and methods for treating or preventing an inflammatory disease, a reperfusion injury, diabetes mellitus, a diabetic complication, reoxygenation injury resulting from organ transplantation, an ischemic condition, a neurodegenerative disease, renal failure, a vascular disease, a cardiovascular disease, cancer, a complication of prematurity, cardiomyopathy, retinopathy, nephropathy, neuropathy, erectile dysfunction or urinary incontinence, comprising administering to a subject in need thereof an effective amount of an Indenoisoquinolinone Analog. | 05-13-2010 |
20100261706 | SUBSTITUTED TETRACYCLIC 1H-INDENO [1,2-B]PYRIDINE-2(5H)-ONE ANALOGS THEREOF AND USES THEREOF - Provided herein are tetracyclic 1H-indeno[1,2-b]pyridine-2(5H)-one analogs and derivatives, compositions comprising an effective amount of a tetracyclic 1H-indeno[1,2-b]pyridine-2(5H)-one analog and/or derivative and methods for treating or preventing an inflammatory disease, a reperfusion injury, diabetes mellitus, a diabetic complication, a reoxygenation injury resulting from organ transplantation, an ischemic condition, a neurodegenerative disease, renal failure, a vascular disease, a cardiovascular disease, an ocular or opthalmologic disease, cancer, a complication of prematurity, cardiomyopathy, retinopathy, nephropathy, contrast induced nephropathy, neuropathy, erectile dysfunction or urinary incontinence, comprising administering to a subject in need thereof an effective amount of a tetracyclic 1H-indeno[1,2-b]pyridine-2(5H)-one analog or derivative. | 10-14-2010 |
20110059961 | 4-SUBSTITUTED PYRIDIN-3-YL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE - The invention relates to compounds of formula (I) which are useful as kinase inhibitors, more specifically useful as PIM kinase inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same, either alone or in combination, to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions. | 03-10-2011 |
20110166334 | ANTIBACTERIAL 4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS HAVING MULTIPLE SUBSTITUENTS - The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection. | 07-07-2011 |
20110245476 | ANTIBACTERIAL 4,6-SUBSTITUTED 6', 6" AND 1 MODIFIED AMINOGLYCOSIDE ANALOGS - The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection. | 10-06-2011 |
20110251176 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE - Pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein X is a thiazolyl, picolinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. | 10-13-2011 |
20120010191 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE - Pyridone and aza-pyridone compounds of Formula I are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. | 01-12-2012 |
20130005674 | ANTIBACTERIAL 4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS HAVING MULTIPLE SUBSTITUENTS - The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection. | 01-03-2013 |
20130039906 | PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE - Pyrazolo[3,4-c]pyridine compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein R | 02-14-2013 |
20130079321 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE - Pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein X is thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. | 03-28-2013 |
20130144044 | ANTIBACTERIAL 4,6-SUBSTITUTED 6', 6'' AND 1 MODIFIED AMINOGLYCOSIDE ANALOGS - The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection. | 06-06-2013 |
20130203732 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE - Pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein X is a thiazolyl, picolinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. | 08-08-2013 |
20130261103 | PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF - Pyridazinone compounds of Formula I including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. | 10-03-2013 |
20130281432 | PYRIDINONES/PYRAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF - Pyridone and pyrazinone compounds of Formula I including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. | 10-24-2013 |
20140005168 | 5-AZAINDAZOLE COMPOUNDS AND METHODS OF USE | 01-02-2014 |
20140057896 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE - Pyridone and aza-pyridone compounds of Formula I are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. | 02-27-2014 |
20140080801 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE - Pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein X is thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. | 03-20-2014 |
20140088117 | CYCLIC ETHER PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE - Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein R | 03-27-2014 |
20140128376 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE - Pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein X is a thiazolyl, picolinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. | 05-08-2014 |
Xueyan Wang, Foster City, CA US
Patent application number | Description | Published |
---|---|---|
20130059856 | AGONISTS OF GPR131 AND USES THEREOF - Chemical compounds which act as agonists of, or otherwise modulate the activity of, GPR131 are disclosed. Related compositions, formulations and methods of use are also described. | 03-07-2013 |
20150290154 | Treatment of NAFLD and NASH - Treatment of NAFLD and NASH by therapy with MBX-8025 or an MBX-8025 salt. | 10-15-2015 |
Yangzhou Wang, Foster City, CA US
Patent application number | Description | Published |
---|---|---|
20130252851 | METHOD OF MAKING A PAIRED TAG LIBRARY FOR NUCLEIC ACID SEQUENCING - The present disclosure relates to methods and compositions for making paired tags and paired tag libraries. | 09-26-2013 |
20150315639 | Method of Making a Paired Tag Library for Nucleic Acid Sequencing - The present disclosure relates to methods and compositions for making paired tags and paired tag libraries. | 11-05-2015 |
Yufang Wang, Foster City, CA US
Patent application number | Description | Published |
---|---|---|
20100330570 | NUCLEOTIDE TRANSIENT BINDING FOR SEQUENCING METHODS - Provided herein are compositions and systems for use in polymerase-dependent, nucleotide transient-binding methods. The methods are useful for deducing the sequence of a template nucleic acid molecule and single nucleotide polymorphism (SNP) analyses. The methods rely on the fact that the polymerase transient-binding time for a complementary nucleotide is longer compared to that of a non-complementary nucleotide. The labeled nucleotides transiently-binds the polymerase in a template-dependent manner, but does not incorporate. The methods are conducted under any reaction condition that permits transient binding of a complementary or non-complementary nucleotide to a polymerase, and inhibits nucleotide incorporation. | 12-30-2010 |
Yulei Wang, Foster City, CA US
Patent application number | Description | Published |
---|---|---|
20090029868 | Expression signature in peripheral blood for detection of aortic aneurysm - We hypothesized that gene expression patterns in peripheral blood cells may correlate with TAA disease status, and carried out a comprehensive gene expression survey on peripheral blood cells obtained from TAA patients and normal individuals. A distinct gene expression profile in peripheral blood cells can classify TAA patients from normal individuals. The genes provided by the present teachings define a set of diagnostic markers, thus providing a blood-based gene expression test to facilitate early detection of TAA disease. Methods of distinguishing ascending from descending TAA are also provided, as are methods of distinguishing familial from sporadic TAA. | 01-29-2009 |
20110159551 | cDNA SYNTHESIS USING A REVERSIBLY INACTIVATED REVERSE TRANSCRIPTASE - The present invention provides compositions and methods for a reverse transcription reaction using a reversibly inactivated reverse transcriptase enzyme. The reversibly inactivated reverse transcriptase enzyme results from a chemical modification which inactivates the reverse transcriptase enzyme. The activity of the reverse transcriptase enzyme is recovered by an incubation of the reaction mixture at elevated temperature prior to, or as part of the reverse transcription reaction. The reverse transcriptase enzyme of the present invention provides for a signficant reduction in non-specific reverse transcription from template nucleic acid molecules because the formulation of the reaction mixture does not support the formation of reverse transcription products prior to activation of the reverse transcriptase. | 06-30-2011 |
20130006342 | EXPRESSION SIGNATURE IN PERIPHERAL BLOOD FOR DETECTION OF AORTIC ANEURYSM - We hypothesized that gene expression patterns in peripheral blood cells may correlate with TAA disease status, and carried out a comprehensive gene expression survey on peripheral blood cells obtained from TAA patients and normal individuals. A distinct gene expression profile in peripheral blood cells can classify TAA patients from normal individuals. The genes provided by the present teachings define a set of diagnostic markers, thus providing a blood-based gene expression test to facilitate early detection of TAA disease. Methods of distinguishing ascending from descending TAA are also provided, as are methods of distinguishing familial from sporadic TAA. | 01-03-2013 |
Zemin Wang, Foster City, CA US
Patent application number | Description | Published |
---|---|---|
20090075279 | Compositions and methods for the diagnosis and treatment of tumor - The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same. | 03-19-2009 |
Zhulun Wang, Foster City, CA US
Patent application number | Description | Published |
---|---|---|
20100048565 | BENZIMIDAZOLE DERIVATIVES - Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of inflammatory and immune-related conditions or disorders. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in inflammation, immune response regulation and cell proliferation. The subject compounds are 2-amino-imidazole derivatives. | 02-25-2010 |